• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 9, 2015

View Archived Issues

ADCs take CAB ride to tumor-town: $1B deal with Pfizer sets Bioatla on development road

Calling Bioatla LLC's Conditionally Active Biologics (CAB) platform "the key piece for getting [an antibody-drug conjugate (ADC)] where it needs to go," CEO Jay Short told BioWorld Today the new deal with Pfizer Inc. represents "the marrying of two world-class technologies." Read More

Alexion's Kanuma A-OK with FDA in first LAL-D nod

The pick-up of Synageva Biopharma Corp. provided an early payback for Alexion Pharmaceuticals Inc., which saw the FDA green-light Kanuma (sebelipase alfa) as the first approved U.S. therapy to treat patients with lysosomal acid lipase deficiency. Read More

Pieris lands $416M I-O pact with Roche for anticalin platform

DUBLIN – Pieris Pharmaceuticals Inc., logged its first partnering deal in immuno-oncology, a pact worth up to CHF415 million (US$416 million) with Roche AG, involving a single undisclosed target against which the German-American biotech will deploy its anticalin scaffold technology. Read More

Akeso's checkpoint-blocking MAb draws MSD in $200M agreement

HONG KONG – Three-year old Chinese novel monoclonal antibody (MAb) developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. The deal comes on the heels of closing a $20 million series A financing funded by local investors. Read More

Precision medicine permeates ASH, and always has

ORLANDO, Fla. – Precision medicine has replaced personalized medicine as the catchphrase of the day, with the change often being explained on the grounds that medicine has always been personalized. Read More

Roche prevails in patent infringement, sort of; Cipla to continue sales

NEW DELHI – Indian generics drugmaker Cipla Ltd. said it will explore all legal options available after an Indian court's recent ruling that the firm infringed the patent rights of Swiss drug major Roche AG regarding lung cancer drug erlotinib. Read More

Sinopharm, Frontline partner to provide series A to Sino Health

SHANGHAI – Getting a drug to patients in China's huge, fractured market is no easy task. But it is a challenge China's state-owned firm, Sinopharm Group, happens to have well under control: It is China's biggest drug distributor, and, not surprisingly, it is the first firm in China's health care sector to make the Fortune 500 list. Last year, Sinopharm's revenues topped $30 billion. Read More

Financings

Tiziana Life Sciences plc, of London, said it raised about £3.8 million (US$5.7 million) through the issue of about 2.6 million unsecured convertible loan notes to investors. Read More

Other news to note

Sunesis Pharmaceuticals Inc., of South San Francisco, submitted a marketing authorization application with the EMA for vosaroxin to treat acute myeloid leukemia (AML) in patients, ages 60 and older. Read More

Stock movers

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe